Ollin Biosciences, Inc. has secured an oversubscribed $330 million in Series B financing to support the ongoing phase 3 clinical investigation of OLN324, its lead candidate for the treatment of two retinal diseases.
Let’s begin with a look at Ollin.
We last heard from the Texas-based biotech company in September 2025 when it debuted with new financing to advance a pipeline of preclinical and late-stage novel therapeutics targeting three serious ocular diseases:
- Diabetic macular edema (DME)
- Thyroid eye disease (TED)
- Wet age-related macular degeneration (AMD)
Read more on this here.
Which of these diseases are the focus of this financing?
That would be DME and wet AMD.
And the candidate in question?
OLN324, a vascular endothelial growth factor (VEGF) / Ang2 bispecific antibody with a higher potency and molar dose as well as a smaller protein format.
- See here for why its higher potency is significant (hint: it has to do with the potential for extended treatment durability).
- Also check out this rundown on a head-to-head, randomized, proof-of-concept phase 1b study, in which OLN324 was compared against faricimab (Vabysmo).
Notably: OLN324's clinical development is in collaboration with Innovent Biologics.
Now backtrack to the new financing.
Here’s what we know: The financing round was co-led by founding investor ARCH Venture Partners and TCGX (a new investor).
- Other participants included: a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), and RA Capital Management.
- Plus, co-founding investors Mubadala Capital and Monograph Capital continued their investments
Gotcha. And it’ll be put toward phase 3 trial trials?
Indeed—global phase 3 development for OLN324.
- Take note: No further details were shared on these planned trials.
Additionally, the financing will also be used to advance another investigational therapy in Ollin’s pipeline: OLN102.
What should we know about that?
As a novel Thyroid-Stimulating Hormone Receptor (TSHR) and Insulin-like Growth Factor 1 Receptor (IGF-1R) bispecific antibody, OLN102 is under clinical development for the treatment of TED and Graves’ diseases.
- See here for why the focus on TSHR and IGF-IR.
The plan: To progress its development later this year.
Alrighty, now in the meantime …has any clinical data been reported yet?
Yes! For OLN324, following that phase 1b study (known as JADE) we mentioned earlier.
Recent data reported from the JADE trial found that OLN324 (versus Vabysmo) demonstrated:
- Faster and more durable drying in DME
- Faster and greater improvements in retinal anatomy for DME and wet AM
- Numerically greater vision gains
One other key stat: 93% of patients did not require retreatment from week 12 to week 20.
Sounds promising … so what’s next for the company?
Ollin shared that it has completed an end-of-phase 2 meeting with the FDA and has plans to initiate global phase 3 trials for OLN324 in both its DME and wet AMD indications.
The timeframe: H2 2026.